Clearside Biomedical presenting additional PEACHTREE data at AAO meeting


Clearside Biomedical (NASDAQ:CLSD) plans to make two presentations at the American Academy of Ophthalmology (AAO) annual meeting on October 27-30 in Chicago, Illinois.

The presentations will highlight positive data from PEACHTREE, the company’s pivotal Phase 3 trial of XIPERE, formerly suprachoroidal CLS-TA, in patients with macular edema associated with non-infectious uveitis.

Dr. Rahul Khurana, a vitreoretinal surgeon at Northern California Retina Vitreous Associates, a clinical associate professor of ophthalmology at UCSF Medical Center and a principal investigator for PEACHTREE, will be making the presentations.

They are “Suprachoroidal Delivery of CLS-TA for Uveitic Macular Edema: Results of the Phase 3 PEACHTREE Trial” and “Phase 3 Efficacy Data of Suprachoroidally Injected CLS-TA for Macular Edema due to Non-infectious Uveitis.”

Dr. Khuranasaid he will be sharing for the first time “additional new analyses that I believe provide further support for the already impressive clinical profile of XIPERE in the treatment of uveitic macular edema.”

Melane LaBelle Sampson